Evaluation of follow-up strategies for patients with epithelial ovarian cancer following completion of primary treatment

Cochrane Database of Systematic Reviews

Volumn 2014, Issue 9, 2014, Pages

  Clarke, Tilean ^a   Galaal, Khadra ^b   Bryant, Andrew ^c   Naik, Raj ^d  

^a LONDON METROPOLITAN UNIVERSITY   (United Kingdom)

^b ROYAL CORNWALL HOSPITAL   (United Kingdom)

^c NEWCASTLE UNIVERSITY   (United Kingdom)

^d QUEEN ELIZABETH HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CA 125 ANTIGEN;

ANTIGEN DETECTION; ANXIETY; BLOOD ANALYSIS; CANCER CHEMOTHERAPY; CANCER MORTALITY; CANCER PATIENT; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER REGRESSION; CANCER SURGERY; CANCER SURVIVAL; CANCER THERAPY; CLINICAL EVALUATION; CLINICAL OUTCOME; COST EFFECTIVENESS ANALYSIS; DETERIORATION; FEMALE; FOLLOW UP; GLOBAL HEALTH; HUMAN; OUTCOME ASSESSMENT; OVARY CARCINOMA; OVERALL SURVIVAL; PATIENT COMPLIANCE; PATIENT PARTICIPATION; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK ASSESSMENT; SYSTEMATIC REVIEW; THERAPY EFFECT; TREATMENT RESPONSE; BLOOD; MORTALITY; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS;

CA-125 ANTIGEN; FEMALE; FOLLOW-UP STUDIES; HUMANS; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84940944913     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD006119.pub3     Document Type: Review

References (100)

1. Rustin GJ, van der Burg ME, Griffin CL, Guthrie D, Lamont A, Jayson GC et al on behalf of MRC and EORTC collaborators. Early versus delayed treatment of relapsed ovarian cancer (MRC OV05/EORTC 55955): a randomised trial. Lancet 2010;376 (9747):1155-63.
2. Alexandre J, Brown C, Coeffic D, Raban N, Pfistere J, Mäenpää J, et al. CA-125 can be part of the tumour evaluation criteria in ovarian cancer trials: experience of the GCIG CALYPSO trial. British Journal of Cancer 2012;106:633-7.
3. Bapsy P. Ovarian cancer. Journal of the Indian Medical Association 2012;110(12):894-7.
4. Buys S, Partridge E, Black A. Screening CA-125 and transvaginal ultrasound does not reduce ovarian cancer mortality. Journal of the National Medical Association 2012;104:116.
5. Fuso L, Evangelista A, Pagano E, Piovano E, Perotto S, Mazzola S. Variation in gynecological oncology follow-up practice: attributable to cancer centers or to patient characteristics? A Piedmont Regional Oncology Network Study. Tumori 2011;97:551-8.
6. Geurts SME, van Altena AM, de Vegt F, Tjan-Heijnen VCG, Massuger LFAG, van Dijck JAAM, et al. No supportive evidence for clinical benefit of routine follow-up in ovarian cancer. A Dutch multicentre study. International Journal of Gynecological Cancer 2011;21(4):647-53.
7. Hall M, Rustin G. Recurrent ovarian cancer: when and how to treat. Current Oncology Reports 2011;13:459-71.
8. Kitajima K, Ueno Y, Suzuki K, Kita M, Ebina Y, Yamada H, et al. Low-dose non-enhanced CT versus full-dose contrast-enhanced CT in integrated PET/CT scans for diagnosing ovarian cancer recurrence. European Journal of Radiology 2012;81:3557-62.
9. Lajtman E, Mlyncek M, Uharcek P, Matejka M. Follow-up after primary therapy of malignant epithelial ovarian tumours (review). Bratislavske Lekarske Listy 2011;112(10):579-85.
10. Madry R, Adamczak-Ratajczak A. The Gordon Rustin revolution - the measurement of CA125 in the surveillance of patients with ovarian cancer. Family Medicine and Primary Care Review 2011;13(2):189-91.
11. Pastalozzi BC. Follow-up: what is evidence-based? Breast and gynecologic tumors. Onkologie 2011;34(6):14.
12. Pignata S, Cannella L, Leopardo D, Bruni GS, Facchini G, Pisano C. Follow-up with CA125 after primary therapy of advanced ovarian cancer: in favor of continuing to prescribe CA125 during follow-up. Annals of Oncology 2011;22(8):40-4.
13. Rustin GJS. Follow-up with CA125 after primary therapy of advanced ovarian cancer has major implications for treatment outcome and trial performances and should not be routinely performed. Annals of Oncology 2011;22(8):45-8.
14. van de Poll-Franse LV, Nicolaije KAH, Vos MC, Pijnenborg JMA, Boll D, Husson O, et al. The impact of a cancer Survivorship Care Plan on gynecological cancer patient and health care provider reported outcomes (ROGY Care): study protocol for a pragmatic cluster randomized controlled trial. Trials Journal 2011;12(256).
15. Lanceley A. A randomised study comparing satisfaction with follow-up led by a trained cancer nurse versus conventional medical follow-up after primary treatment for ovarian cancer. [: ISRCTN59149551]
16. Aebi S, Castiglione M. Epithelial ovarian carcinoma: ESMO Clinical Recommendations for diagnosis, treatment and follow-up. Annals of Oncology 2008;19(Suppl 2):ii14-6.
17. Barnhill D, O'Connor D, Farley J, Teneriello M, Armstrong D, Park R. Clinical surveillance of gynecologic cancer patients. Gynecological Oncology 1992;46(3):275-80.
18. Barzen G, Cordes M, Langer M, Friedman W, Mayr AC, Felix R. Value of radioimmunoscintigraphy compared to computed tomography in the diagnosis and follow-up of primary ovarian carcinoma. RöFo:Fortschritte auf dem Gebiete der Röntgenstrahlen und derNuklearmedizin 1990;153(1):85-91.
19. Bradley E, Pitts M, Redman C, Calvert E, Howells R, Wafai C. What are the factors associated with the follow-up preferences of women in long-term remission from gynaecological cancer?. Journal of Obstetrics and Gynaecology 2000;20(4):408-11.
20. Bristow RE, Puri I, Chi DS. Cytoreductive surgery for recurrent ovarian cancer: a meta-analysis. Gynecologic Oncology 2009;112(1):265-74.
21. Bruzzone M, Onetto M, Campora E, Chiara S, Oliva C, Guido T, et al. CA-125 monitoring in the management of ovarian cancer. Anticancer research 1990;10(5A):1353-9.
22. Cerejeira L, Pinto FMM, Otilia BMO, Moutinho J. Validity of gynaegnost in the follow-up of patients treated for ovarian cancer. Revue Française de Gynécologie et d'Obstétrique 1989;84(4):347-9.
23. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
24. Crombach G, Zippel HH, Würz H. Clinical significance of cancer antigen 125 CA 125 in ovarian cancer. Cancer detection and prevention 1985;8(1-2):135-9.
25. Dachman AH, Visweswaran A, Battula R, Jameel S, Waggoner SE. Role of chest CT in the follow-up of ovarian adenocarcinoma. American Journal of Roentgenology 2001;176(3):701-5.
26. Engblom PR, Grènman SE, Klemi PJ, Hirvonen TE, Rantanen VT, Salmi TA. The role of cul-de-sac aspiration cytology in the follow-up of ovarian cancer. Acta Oncologica (Stockholm Sweden) 1995;34(6):783-5.
27. Sant M, Aareleid T, Berrino F, Bielska Lasota M, Carli PM, Faivre J et al and the EUROCARE Working Group. EUROCARE-3: survival of cancer patients diagnosed 1990-94-results and commentary. Annals of Oncology 2003;14 (Supplement 5):v61-v118.
28. Fayed ST, Ahmad SM, Kassim SK, Khalifa A. The value of CA 125 and CA72-4 in management of patients with epithelial ovarian cancer. Disease Markers 1998;14(3):155-60.
29. Fehm T, Heller F, Krämer S, Jäger W, Gebauer G. Evaluation of CA125, physical and radiological findings in follow-up of ovarian cancer patients. Anticancer Research 2005;25(3A):1551-4.
30. Fioretti P, Gadducci A, Ferdeghini M, Prontera C, Malagnino G, Facchini V, et al. The concomitant determination of different serum tumor markers in epithelial ovarian cancer: relevance for monitoring the response to chemotherapy and follow-up of patients. Gynecologic Oncology 1992;44(2):155-60.
31. Fisken J, Leonard RC, Shaw G, Bowman A, Roulston JE. Serum placental-like alkaline phosphatase PLAP: a novel combined enzyme linked immunoassay for monitoring ovarian cancer. Journal of Clinical Pathology 1989;42(1):40-5.
32. Gadducci A, Marrai R, Baicchi U, Ferdeghini M, Fanucchi A, Facchini V, et al. The measurement of plasma D-dimer DD levels in the follow-up of patients with ovarian cancer. Anticancer Research 1995;15(6B):2683-6.
33. Gadducci A, Cosio S, Zola P, Landoni F, Maggino T, Sartori E. Surveillance procedures for patients treated for epithelial ovarian cancer: a review of the literature. International Journal of Cancer 2007;17(1):21-31.
34. García VMJ, Boán GJF, Villar LLM, Aramendía BJM, López GG, Richter EJA. F-18-FDG positron emission tomography in the diagnosis of ovarian recurrence. Comparison with CT scan and CA 125. Revista Espanola de Medicina Nuclear 2003;22(4):217-23.
35. Garzetti GC, Di LRM, Ciavattini A, Pallotta MR, Marchegiani F, Valensise H, et al. Tumor markers in the early diagnosis of recurrence in gynecologic neoplasms: combined determination of CA-125, CA 15-3, CA 724, SCC, 90 K. Annali di Ostetricia, Ginecologia, Medicina Perinatale 1991;112(5):320-3.
36. Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C. GLOBOCAN 2012. Cancer incidence, mortality worldwide. IARC CancerBase No. 11, version 1.0. IARCPress, Lyon 2012.
37. Goonewardene TI, Hall MR, Rustin GJS. Management of asymptomatic patients on follow-up for ovarian cancer with rising CA-125 concentrations. Lancet Oncology 2007;8(9):813-21.
38. Grabiec M, Walentowicz M, Nowicki P. The value of FDG PET/CT, ultrasound and CT in diagnosing recurrent ovarian carcinoma. Ginekologia Polska 2006;77(10):746-52.
39. GRADE Working Group. Grading quality of evidence and strength of recommendations. BMJ 2004;328:1490-4.
40. Gritzmann N, Karnel F, Imhof H, Wagner G, Müller T E, Dittrich C. Abdominal computerized tomography in the after-care of ovarian cancers. Digitale Bilddiagnostik 1986;6(4):171-5.
41. Grunfeld E, Mant D, Yudkin P, Adewuyi-Dalton R, Cole D, Stewart J, et al. Routine follow up of breast cancer in primary care: randomised trial. BMJ 1996;313:665-9.
42. Hauth EAM, Antoch G, Stattaus J, Kuehl H, Veit P, Bockisch A, et al. Evaluation of integrated whole-body PET/CT in the detection of recurrent ovarian cancer. European Journal of Radiology 2005;56(2):263-8.
43. Hernádi Z, Molnár V, Juhász B, Pólka R, Margitai B. Predictive value of the tumor marker combination CA-125 and beta-2-microglobulin in ovarian cancer. Zentralblatt für Gynäkologie 1992;114(1):6-9.
44. Hetzel H, Bichler A, Fuchs D, Hausen A, Reibnegger G, Wachter H. Significance of urinary neopterine in gynecological oncology: follow-up of patients with ovarian cancer. Cancer Detection and Prevention 1983;6(1-2):263-6.
45. Hising C, Anjegård IM, Einhorn N. Clinical relevance of the CA 125 assay in monitoring of ovarian cancer patients. American Journal of Clinical Oncology 1991;14(2):111-4.
46. Parkin DM, Whelan SL, Ferlay J, Teppo L, Thomas DB. Cancer Incidence in Five Continents, Volume VIII. In: Parkin DM, Whelan SL, Ferlay J, Teppo L, Thomas DB editor(s). IARC Scientific Publication No 155. Lyon: IARC Scientific Publication, 2002.
47. Inoue M, Fujita Y, Abe Y, Inoue Y, Ueda G, Tanizawa O, et al. Tissue polypeptide antigen as a tumor marker for gynecologic malignancies. Nippon Sanka Fujinka Gakkai Zasshi 1985;37(9):1799-805.
48. Iwanari O, Miyako J, Date Y, Moriyama M, Yoshino N, Kijima S, et al. Diagnosis and follow-up of ovarian cancer by a combination assay of serum sialyl SSEA-1 antigen and CA125 levels. Nippon Gan Chiryo Gakkai Shi 1989;24(6):1256-60.
49. Javitt MC. ACR Appropriateness Criteria on staging and follow-up of ovarian cancer. Journal of the American College of Radiology 2007;4(9):586-9.
50. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T. Cancer statistics. CA: A Cancer Journal for Clinicians 2008;58:71-96.
51. Kaesemann H, Caffier H, Hoffmann FJ, Crombach G, Würz H, Kreienberg R, et al. Monoclonal antibodies in the diagnosis and follow-up of ovarian cancer CA 125 as a tumor marker A cooperative study of the Gynecologic Tumor Marker Group GTMG. Klinische Wochenschrift 1986;64(17):781-5.
52. Kerr-Wilson RH, McCrum A. Follow-up of patients with gynaecological cancer. Australian and New Zealand Journal of Obstetrics and Gynaecology 1995;35(3):298-9.
53. Kew FM, Roberts AP, Cruickshank DJ. The role of routine follow-up after gynecological malignancy. International Journal of Gynecological Cancer 2005;15(3):413-9.
54. Kew FM, Cruickshank DJ. Routine follow up after treatment for a gynaecological cancer: a survey of practice. International Journal of Gynecological Cancer 2006; Vol. 16:380-4.
55. Khan O, Cosgrove DO, Fried AM, Savage PE. Ovarian carcinoma follow-up: US versus laparotomy. Radiology 1986;159(1):111-3.
56. Khoo SK, Mackay EV. Carcinoembryonic antigen by radioimmunoassay in the detection of recurrence during long-term followup of female genital cancer. Cancer 1974;34(3):542-8.
57. Khoo SK, Whitaker S, Jones I, Mackay E. Predictive value of serial carcinoembryonic antigen levels in long-term follow-up of ovarian cancer. Cancer 1979;43(6):2471-8.
58. Kim CK, Park BK, Choi JY, Kim B-G, Han H. Detection of recurrent ovarian cancer at MRI: comparison with integrated PET/CT. Journal of Computer Assisted Tomography 2007;31(6):868-75.
59. Kitajima K, Murakami K, Yamasaki E, Domeki Y, Kaji Y, Fukasawa I, et al. Performance of integrated FDG-PET/contrast-enhanced CT in the diagnosis of recurrent ovarian cancer: comparison with integrated FDG-PET/non-contrast-enhanced CT and enhanced CT. European Journal of Nuclear Medicine & Molecular Imaging 2008;35(8):1439-48.
60. Kobayashi H. Clinical usefulness of serum sialyl Lex-i measurement in patients with ovarian cancer. Nippon Sanka Fujinka Gakkai Zasshi 1989;41(1):15-9.
61. Kubik HRA, Dörffler W, von SGK, Marincek B, Köchli OR, Seifert B, et al. Value of 18F-FDG positron emission tomography, computed tomography, and magnetic resonance imaging in diagnosing primary and recurrent ovarian carcinoma. European Radiology 2000;10(5):761-7.
62. Kunkler IH, Kerr GR, Ludgate SM. The value of follow-up in stage II. carcinoma of the cervix. Clinical Oncology 1991;3(1):28-31.
63. Lahousen M, Stettner H, Pickel H, Urdl W, Pürstner P. The predictive value of a combination of tumor markers in monitoring patients with ovarian cancer. Cancer 1987;60(9):2228-32.
64. Lenehan PM, Dembo AJ, Miceli PN, Malkin DG, Malkin A. Clinical correlations of carcinoembryonic antigen in post-operative patients with epithelial ovarian cancer. Tumour Biology: the journal of the International Society for Oncodevelopmental Biology and Medicine 1986;7(5-6):389-405.
65. Lenhard MS, Burges A, Johnson TR, Stieber P, Kumper C, Ditsch N, et al. PET-CT in recurrent ovarian cancer: impact on treatment planning. Anticancer Research 2008;28(4C):2303-8. [PUBMED: 18751410]
66. Low RN, Saleh F, Song SY, Shiftan TA, Barone RM, Lacey CG, et al. Treated ovarian cancer: comparison of MR imaging with serum CA-125 level and physical examination--a longitudinal study. Radiology 1999;211(2):519-28.
67. Mangili G, Picchio M, Sironi S, Vigano R, Rabaiotti E, Bornaghi D, et al. Integrated PET/CT as a first-line re-staging modality in patients with suspected recurrence of ovarian cancer. European Journal of Nuclear Medicine & Molecular Imaging 2007;34(5):658-66.
68. Menczer J, Chetrit A, Sadetzki S, Golan A, Levy T. Follow-up of ovarian and primary peritoneal carcinoma: the value of physical examination in patients with pretreatment elevated CA125 levels. Gynecologic Oncology 2006;103(1):137-40.
69. Moore S, Corner J, Haviland J, Wells M, Salmon E, Normand C, et al. Nurse led follow up and conventional medical follow up in management of patients with lung cancer: randomised trial. BMJ 2002;325:1145.
70. Nakamoto Y, Saga T, Ishimori T, Mamede M, Togashi K, Higuchi T, et al. Clinical value of positron emission tomography with FDG for recurrent ovarian cancer. American Journal of Roentgenology 2001;176(6):1449-54.
71. Oehler MK, Sütterlin M, Caffier H. CASA and Ca 125 in diagnosis and follow-up of advanced ovarian cancer. Anticancer Research 1999;19(4A):2513-8.
72. Okai T, Kagawa H, Masuda H, Kozuma S, Mizuno M. Assessment of ovarian tumors by transvaginal scanning and clinical significance of ultrasonic examination in postoperative follow up. Rinsho Byori. The Japanese Journal of Clinical Pathology 1992;40(4):363-8.
73. Olaitan A, Murdoch J, Anderson R, James J, Graham J, Barley V. A critical evaluation of current protocols for the follow-up of women treated for gynecological malignancies: a pilot study. International Journal of Gynecologic Cancer 2001;11(5):349-53.
74. Palmer C, Pratt J, Basu B, Earl H. A study to evaluate the use of CA125 in ovarian cancer follow-up: a change in practice led by patient preference. Gynecologic Oncology 2006;101(1):4-11.
75. Parker PA, Kudelka A, Basen-Engquist K, Kavanagh J, de Moor J, Cohen L. The associations between knowledge, CA125 preoccupation, and distress in women with epithelial ovarian cancer. Gynecologic Oncology 2006;100(3):495-500. [PUBMED: 16242759]
76. Parmar MK, Torri V, Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Erratum in Statistics in Medicine 2004 Jun 15;23(11):1817. Statistics in Medicine 1998 Dec 30;17(24):2815-34.
77. Prayer L, Kainz C, Kramer J, Stiglbauer R, Schurawitzki H, Baldt M, et al. CT and MR accuracy in the detection of tumor recurrence in patients treated for ovarian cancer. Journal of Computer Assisted Tomography 1993;17(4):626-32.
78. Renehan AG, Egger M, Saunders MP, O'Dwyer ST. Impact on survival of intensive follow up after curative resection for colorectal cancer: systematic review and meta-analysis of randomised trials. BMJ 2002;324:813.
79. Renehan AG, Egger M, Saunders MP, O'Dwyer ST. Mechanisms of improved survival from intensive follow up in colorectal cancer: a hypothesis. British Journal of Cancer 2005;92(3):430-3.
80. Roberts K, Clarke C. Future disorientation following gynaecological cancer: Women's conceptualisation of risk after a life threatening illness. Health, Risk & Society 2009;11(4):353-366.
81. Rustin G, Tuxen M. Use of CA 125 in follow-up of ovarian cancer. Lancet 1996;348(9021):191-2.
82. Schorge JO, Drake RD, Lee H, Skates SJ, Rajanbabu R, Miller DS, et al. Osteopontin as an adjunct to CA125 in detecting recurrent ovarian cancer. Clinical Cancer Research: an official journal of the American Association for Cancer Research 2004;10(10):3474-8.
83. Sella T, Rosenbaum E, Edelmann DZ, Agid R, Bloom AI, Libson E. Value of chest CT scans in routine ovarian carcinoma follow-up. American Journal of Roentgenology 2001;177(4):857-9.
84. Shimizu Y, Akagaki E, Hirota K, Kono M, Miura S, Okudaira Y, et al. Significance of immunosuppressive acidic protein in the diagnosis and follow-up of patients with ovarian cancer, in particular as a marker for chemotherapeutic effects. Nippon Sanka Fujinka Gakkai Zasshi 1986;38(4):554-60.
85. Shinozuka T, Miyamoto T, Hirazono K, Ebisawa K, Murakami M, Kuroshima Y, et al. Follow-up laparoscopy in patients with ovarian cancer. The Tokai Journal of Experimental and Clinical Medicine 1994;19(1-2):53-9.
86. Sliutz G, Tempfer C, Kainz C, Mustafa G, Gitsch G, Koelbl H, et al. Tissue polypeptide specific antigen and cancer associated serum antigen in the follow-up of ovarian cancer. Anticancer Research 1995;15(3):1127-9.
87. Stewart DE, DuffS, Wong F, Melancon C, Cheung AM. The views of ovarian cancer survivors on its cause, prevention, and recurrence. Medscape Women's Health 2001;6(5):5.
88. Sugiyama Y, Shimizu Y, Umezawa S, Yamauchi K, Hasumi K. Feasibility of peritoneal washing cytology through the totally implanted reservoir for early detection of peritoneal recurrence of ovarian cancer. Nippon Sanka Fujinka Gakkai Zasshi 1996;48(3):213-9.
89. Tempfer C, Hefler L, Haeusler G, Reinthaller A, Koelbl H, Zeisler H, et al. Tissue polypeptide specific antigen in the follow-up of ovarian and cervical cancer patients. International Journal of Cancer. Journal International du Cancer 1998;79(3):241-4.
90. Testa AC, Ciampelli M, Mastromarino C, Lopez R, Zannoni GF, Mancuso S, et al. Detection of central pelvic recurrent disease with transvaginal color Doppler ultrasound in women treated for gynecological malignancy. Ultrasound in Obstetrics & Gynecology 2002;19(5):490-5.
91. Testa AC, Fruscella E, Ludovisi M, De V Rosa, Malaggese M, Corrado G, et al. The role of sonographic examination in the follow-up of gynecological neoplasms. Gynecologic Oncology 2005;99(3):696-703.
92. Thrall MM, DeLoia JA, Gallion H, Avril N. Clinical use of combined positron emission tomography and computed tomography FDG-PET/CT in recurrent ovarian cancer. Gynecologic Oncology 2007;105(1):17-22.
93. Torizuka T, Nobezawa S, Kanno T, Futatsubashi M, Yoshikawa E, Okada H, et al. Ovarian cancer recurrence: role of whole-body positron emission tomography using 2-fluorine-18-fluoro-2-deoxy- D-glucose. European Journal of Nuclear Medicine and Molecular Imaging 2002;29(6):797-803.
94. Tuxen MK, Sölétormos G, Dombernowsky P. Serum tumor marker CA 125 for monitoring ovarian cancer during follow-up. Scandinavian Journal of Clinical and Laboratory Investigation 2002;62(3):177-88.
95. Vaidya AP, Curtin JP. The follow-up of ovarian cancer. Seminars in Oncology 2003;30(3):401-12.
96. VillaSanta U, Jovanovski D. Follow-up study of ovarian carcinoma by cytology of cul-de-sac aspirates. Gynecologic Oncology 1980;10(1):58-62.
97. Vinokurov VL, Dudarev AL, Jurkova LE, Lapchenkov VI, Barbanel EJ. Tumor marker CA 125 in diagnosis, monitoring management and follow-up of patients with ovarian tumors. European Journal of Gynaecological Oncology 1992;13(2):205-8.
98. Vuento M, Salmi T, Klemi P, Grénman S. Ultrasonographic-guided pervaginal cul-de-sac cytology in the follow-up of ovarian carcinoma. Anticancer Research 2007;27(2):1015-8.
99. Zhu X, Shen K, Lang J, Wu M, Huang H, Pan L. Role of positron emission tomography in detecting recurrent epithelial ovarian carcinoma. Zhonghua Fu Chan Ke za Zhi 2002;37(6):356-8.
100. Zimny M, Siggelkow W, Schröder W, Nowak B, Biemann S, Rath W, et al.2-Fluorine-18-fluoro-2-deoxy-d-glucose positron emission tomography in the diagnosis of recurrent ovarian cancer. Gynecologic Oncology 2001;83(2):310-5.